I cannot figure this stock out. They have their intravitreal complement inhibitor in trials for dry AMD. In both the original IPO S3 and recent filings/presentations shows that they can delay the progression of dry AMD. But, there seems to be a big issue here in that there is significant development of wet AMD in some treated patients.
I sold out of APLS when this was highlighted after their successful IPO, and that bothered me. Not sure why this is not a big deal for more investors. Does anyone have thoughts on this? Sure there are treatments for wet AMD, but nevertheless...
Market Data 
Markets 
AI
